• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.

作者信息

Tenenbaum Alexander, Motro Michael, Fisman Enrique Z, Leor Jonathan, Boyko Valentina, Mandelzweig Lori, Behar Solomon

机构信息

Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.

出版信息

Cardiology. 2003;100(4):207-15. doi: 10.1159/000074814.

DOI:10.1159/000074814
PMID:14713732
Abstract

BACKGROUND

Some patients developing heart failure and functional capacity impairment have no history of myocardial infarction (MI), and stable angina pectoris is their principal clinical manifestation of coronary artery disease (CAD). The present study was aimed to evaluate the outcome of CAD-related functional capacity impairment in patients with and without a history of MI over a 7.7-year follow-up.

METHODS

The study sample comprised 14,283 coronary patients aged 45-74 years, screened for participation in the Bezafibrate Infarction Prevention study. The presence of NYHA functional class II was defined as mild functional capacity impairment and the presence of NYHA functional class III-IV was defined as advanced functional capacity impairment.

RESULTS

The patients were divided in two groups: (1) those with a history of MI, 10,307 patients, who formed three subgroups: NYHA I 7,551 patients (73.3%); NYHA II 2,176 patients (21.1%); NYHA III + IV 580 patients (5.6%), and (2) those without a history of MI, 3,976 patients, who also formed three subgroups: NYHA I 2,744 patients (69.0%); NYHA 981 patients (24.7%); NYHA III + IV 251 patients (6.3%). Multivariate analysis identified a history of MI as a consistent predictor of increased all-cause and cardiac mortality for patients with NYHA I, II and III + IV subgroups with escalating significance for patients with advanced functional capacity impairment: hazard ratios of 1.55 (95% CI 1.36-1.75), 1.56 (95% CI 1.30-1.86) and 1.72 (95% CI 1.24-2.40) for all-cause and 1.93 (95% CI 1.60-2.33), 1.73 (95% 1.35-2.20) and 3.22 (95% CI 1.87-5.54) for cardiac mortality, respectively.

CONCLUSIONS

The prevalence of low functional capacity is similar among coronary patients with and without a history of MI, but their long-term survival differs substantially in favor of the latter. Therefore, two different types of CAD-related advanced functional capacity impairments (post-MI and non-post-MI) can be distinguished.

摘要

相似文献

1
Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.
Cardiology. 2003;100(4):207-15. doi: 10.1159/000074814.
2
Functional class in patients with heart failure is associated with the development of diabetes.
Am J Med. 2003 Mar;114(4):271-5. doi: 10.1016/s0002-9343(02)01530-9.
3
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.CHARM(坎地沙坦心力衰竭评估减少死亡率和发病率)计划中心绞痛和心力衰竭患者的临床特征和结局。
Eur J Heart Fail. 2015 Feb;17(2):196-204. doi: 10.1002/ejhf.221.
4
Comparison of clinical characteristics and prognosis in Taiwanese patients with coronary vasospastic angina pectoris without significant fixed coronary artery disease versus patients with significant fixed coronary artery disease and either stable angina pectoris or acute coronary syndromes.台湾地区无显著固定性冠状动脉疾病的冠状动脉痉挛性心绞痛患者与患有显著固定性冠状动脉疾病且伴有稳定型心绞痛或急性冠状动脉综合征患者的临床特征及预后比较。
Am J Med Sci. 2007 Sep;334(3):160-7. doi: 10.1097/MAJ.0b013e3181405b30.
5
Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden.中年男性普通人群样本中心肌梗死和心绞痛的自然病史:瑞典哥德堡初级预防研究的16年随访
J Intern Med. 1998 Dec;244(6):495-505. doi: 10.1111/j.1365-2796.1998.00394.x.
6
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.冠心病和心绞痛患者的临床特征和结局:心力衰竭伴射血分数保留患者应用伊贝沙坦的分析试验。
Circ Heart Fail. 2015 Jul;8(4):717-24. doi: 10.1161/CIRCHEARTFAILURE.114.002024. Epub 2015 Jun 11.
7
Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.基于纽约心脏协会分级的功能状态不佳使冠心病患者面临缺血性中风风险升高的情况。
Am Heart J. 2008 Mar;155(3):515-20. doi: 10.1016/j.ahj.2007.10.032. Epub 2008 Jan 31.
8
Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS Study Group.卡托普利与地高辛治疗冠心病合并轻度心力衰竭患者的疗效比较。一项前瞻性、双盲、安慰剂对照的多中心研究。冠心病合并心力衰竭研究组。
Herz. 1993 Dec;18 Suppl 1:436-43.
9
[Hemodynamics and clinical data in chronic coronary disease with severe left ventricular systolic dysfunction].[重度左心室收缩功能不全的慢性冠状动脉疾病的血流动力学与临床数据]
Cardiologia. 1996 Apr;41(4):349-59.
10
Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III. The Bezafibrate Infarction Prevention (BIP) Study Group.β受体阻滞剂治疗对纽约心脏协会心功能Ⅱ级和Ⅲ级冠心病患者的影响。非诺贝特预防心肌梗死(BIP)研究组。
Am J Cardiol. 1998 Jun 15;81(12):1455-60. doi: 10.1016/s0002-9149(98)00205-7.

引用本文的文献

1
Longitudinal strain correlates with 6-minute walk distance whereas ejection fraction and diastolic parameters do not.纵向应变与 6 分钟步行距离相关,而射血分数和舒张参数则不相关。
Cardiovasc Ultrasound. 2024 Jun 7;22(1):6. doi: 10.1186/s12947-024-00325-z.
2
Is there any relationship between cardiopulmonary capacity and cardiovascular mechanics in coronary artery disease?冠心病患者的心肺功能与心血管力学之间存在关联吗?
Anatol J Cardiol. 2016 Aug;16(8):614-615. doi: 10.14744/AnatolJCardiol.2016.19711.
3
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
过氧化物酶体增殖物激活受体配体苯扎贝特对功能能力严重受损患者N末端B型利钠肽的长期影响。
Cardiovasc Diabetol. 2009 Jan 28;8:5. doi: 10.1186/1475-2840-8-5.